Sarepta Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
SRPT Nasdaq 8731 https://www.sarepta.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Sarepta Therapeutics Inc

Why Is Sarepta Therapeutics (SRPT) Down 1.5% Since Last Earnings Report? - Jun 1st, 2023 3:31 pm
15 Best Healthcare Stocks To Buy Now - Jun 1st, 2023 2:04 pm
Is Sarepta Therapeutics' Gene Therapy in Danger of Not Obtaining FDA Approval? - Jun 1st, 2023 10:45 am
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 31st, 2023 10:16 pm
Sarepta Therapeutics Dives On An Unexpected Holdup For Its Gene Therapy - May 24th, 2023 8:04 pm
Why Shares of Sarepta Therapeutics Are Dropping Wednesday - May 24th, 2023 5:53 pm
FDA Extends Review For Sarepta Therapeutics' Duchenne Gene Therapy By Couple Of Weeks - May 24th, 2023 4:28 pm
2 Under-the-Radar Biotech Stocks to Buy in 2023 - May 24th, 2023 1:53 pm
UPDATE 2-FDA defers decision for Sarepta's gene therapy to June 22 from May 29 - May 24th, 2023 12:24 pm
Sarepta Therapeutics Announces Update on Regulatory Review of SRP-9001 - May 24th, 2023 12:00 pm
Why These 3 Nasdaq Stocks Buckled Today - May 16th, 2023 7:42 pm
Gene-Therapy Investors Have a Powerful Ally: Patients - May 16th, 2023 12:30 pm
Sarepta Stock Catapults Higher After Eking Out A Narrow Win In Its Gene Therapy Battle - May 15th, 2023 8:05 pm
Stocks to Watch Monday: Newmont, Oneok, Shake Shack - May 15th, 2023 4:48 pm
Why Sarepta Therapeutics Stock Is Skyrocketing Today - May 15th, 2023 2:59 pm
Sarepta gains over $2B in market cap on new hope for Duchenne drug approval - May 15th, 2023 2:30 pm
FDA AdComm Narrowly Supports Approval Of Sarepta's Gene Therapy For Rare Neuromuscular Disorder - May 15th, 2023 12:53 pm
Sarepta surges after FDA panel backs Duchenne gene therapy - May 15th, 2023 12:33 pm
2 Supercharged Growth Stocks to Buy Right Now - May 14th, 2023 8:00 pm
Sarepta Therapeutics Announces Positive Vote from U.S. FDA Advisory Committee Meeting for SRP-9001 Gene Therapy to Treat Duchenne Muscular Dystrophy - May 12th, 2023 11:02 pm